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ESTUDIO DE LA INERVACIÓN CORNEAL Y LA UNIDAD 
FUNCIONAL LAGRIMAL EN PACIENTES TRATADOS CON 
LATANOPROST EN COLIRIO MONODISIS 
RESUMEN 
El tratamiento médico crónico es la primera opción para tratar el glaucoma primario de 
ángulo abierto (GPAA) e hipertensión ocular (OH).  
El objetivo de este estudio fue evaluar los efectos del latanoprost sin conservante en 
las características de la película lagrimal, la sensibilidad corneal y la inervación. 
En el grupo de tratamiento se incluyeron 31 ojos de 31 pacientes y 30 ojos de 
voluntarios sanos sirvieron de controles. Se analizó la sensibilidad corneal, 
microscopia confocal (IVCM), la osmolaridad lagrimal, el tiempo de ruptura lagrimal, y 
la prueba de Schirmer I. 
Los resultados mostraron una reducción significativa entre el grupo de tratamiento y el 
grupo control en algunos de los test clínicos. Se encontraron una disminución 
significativas del número y la densidad de los nervios sub-basal y un aumento 
significativo de la densidad de las células epiteliales basales en el grupo con 
tratamiento. 
Conclusiones: Los ojos con tratamiento con latanoprost tópico sin conservantes 
sufrirían pérdida de sensibilidad corneal, disminución del BUT y reducción del número 
y densidad de los nervios del plexo subbasal de la córnea. La acción proinflamatoria 
del fármaco u otros excipientes podrían producir estos efectos nocivos sobre la 
superficie ocular. 
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ESTUDI DE LA INNERVACIÓ CORNEAL I LA UNITAT 
FUNCIONAL LACRIMAL EN PACIENTS TRACTATS AMB 
LATANOPROST AMB COLIRI MONODOSI  
RESUM 
El tractament mèdic crònic és la primera opció per tractar el glaucoma primari d'angle 
obert (GPAA) i la hipertensió ocular (OH). 
L'objectiu d'aquest estudi va ser avaluar els efectes del latanoprost sense conservant 
en les característiques de la pel·lícula lacrimal, la sensibilitat corneal i la seva 
innervació. 
En el grup de tractament s’inclogueren 31 ulls de 31 pacients i 30 ulls de voluntaris 
sans van servir de controls. Es va analitzar la sensibilitat corneal, microscopia 
confocal (IVCM) l'osmolaritat lacrimal, el temps de ruptura lacrimal, la tinció corneal 
amb fluoresceïna, els símptomes i la prova de Schirmer I. 
Els resultats van mostrar una reducció significativa entre el grup de tractament i el 
grup control en alguns dels tests clínics. Es van trobar un descens significatiu del 
nombre i densitat dels nervis corneals sub-basals i un augment significatiu de la 
densitat de les cèl·lules epitelials basals en el grup amb tractament. 
Conclusions: Els ulls amb tractament amb latanoprost tòpic sense conservants 
patirien pèrdua de sensibilitat corneal, descens del BUT i reducció del nombre i 
densitat dels nervis del plexe subbasal de la còrnia. La acció proinflamatòria del 
fàrmac o altres excipients podrien produir aquests efectes nocius sobre al superfície 
ocular. 
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TEAR FILM CHARACTERISTICS, CORNEAL SENSITIVITY 
AND INNERVATION IN EYES WITH TOPICAL 
LATANOPROST WITHOUT PRESERVATIVE 
ABSTRACT 
Chronic medical therapy is the usual first choice to treat primary open-angle glaucoma 
(POAG) and ocular hypertension (OH). 
The aim of this study was to evaluate the effects of topical latanoprost without 
preservative on tear film characteristics, corneal sensitivity and innervation. 
In the treatment group 31 eyes of 31 patients were finally included and 30 eyes of 
healthy volunteers served as controls. We analyzed the corneal sensitivity, confocal 
microscopy (IVCM) tear osmolarity, tear breakup time, corneal fluorescein staining, 
symptoms and test Schirmer I. 
The results showed a significant reduction between the treatment group and the 
control group in some of the clinical tests. We found a significant decrease in the 
number and density of corneal sub-basal nerve and a significant increase in the 
density of basal epithelial cells in the treatment group. 
Conclusions: Eyes with chronic treatment with free-preservative topical latanoprost 
seems to undergo loss of corneal sensitivity, BUT decrease and reduction in the 
number and length of corneal subbasal nerves. The proinflammatory drug effect or 
other excipients than preservative could produce this harmful effects on the ocular 
surface. 
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COVER LETTER 
Dear Editor, 
Attached you will find the paper entitled "Tear film characteristics, corneal sensitivity 
and innervation in eyes with topical latanoprost without preservative”, which we are 
submitting for publication in Cornea Journal as an original article. 
To evaluate tear film characteristics, corneal sensitivity and innervation in eyes with 
topical latanoprost without preservative. We analyzed the corneal sensitivity, confocal 
microscopy (IVCM), tear osmolarity, tear breakup time, corneal fluorescein staining, 
symptoms and test Schirmer I. 
We would be very grateful for any comments or suggestions you may wish to make. 
Thank you for your attention. 
Yours sincerely, 
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ABSTRACT 
PURPOSE: To evaluate tear film characteristics, corneal sensitivity and innervation in 
eyes with topical latanoprost without preservative. 
METHODS: In the treatment group 31 eyes of 31 patients (mean age 63 ± 13; range 
35-89) were included, from those, 25 (81%) with POAG and 6 with ocular 
hypertension. Mean time of treatment was 8 ± 6 months (range= 3-24 months). Thirty 
healthy eyes served as a control. Corneal sensitivity, tear osmolarity, tear break-up 
time (BUT), fluorescein staining, symptoms, and Schirmer I test were carried-out. 
Density of basal epithelial cells, subbasal nerve number and length were measured by 
in vivo confocal microscopy images. 
RESULTS: A significant reduction of the scores was found in the treatment group in 
corneal sensitivity and BUT and a singificant increase in ocular symptoms of 
discomfort (p < 0.05). No statistically significant differences were found in the rest of 
studied clinical characteristics.  
The density of basal epithelial cells was significantly increased in the treatment group 
(p =0.008, Student t test). The number of sub-basal nerves was lower in treatment 
group than in the control group (p=0.002, Student t test)  and the density of sub-basal 
nerves was significantly lower in treatment group (p =0.005, Student t test). 
CONCLUSIONS: Eyes with chronic treatment with free-preservative topical 
latanoprost seems to undergo loss of corneal sensitivity, BUT decrease and reduction 
in the number and length of corneal subbasal nerves. The proinflammatory drug effect 
or other excipients than preservative could produce this harmful effects on the ocular 
surface. 
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MAIN TEXT 
INTRODUCTION 
Primary open-angle glaucoma (POAG), also known as chronic open-angle glaucoma 
can be defined as an optic neuropathy characterized by changes in the optic nerve 
headand visual field deterioration, with or without ocular hypertension. 
In general, the primary open-angle glaucoma is an asymptomatic condition.  However, 
abrupt or significant increases in intraocular pressure (IOP) occur with decreased 
visual field, eye pain and discomfort  
Glaucoma is the second leading cause of blindness in the world, the economic and 
social repercussions are enormous, so today represent a public health problem.1 
Some of the most important factors associated with progression of glaucomatous optic 
neuropathy are advanced age, a high level of intraocular pressure (IOP), 
pseudoexfoliation and hemorrhages on the optical disc. About hypertension 
progression factors, the most importants are: high levels of IOP, advanced age, central 
corneal thickness and bleeding on the optical disc.2 Although, IOP plays a very 
important role in the genesis of this multifactorial disease.  
Epidemiological studies suggest that only a tenth part of the patients with elevated 
pressures have glaucomatous visual field loss. However, about five-sixths of them with 
glaucomatous disk and changes in the visual field have increased intraocular pressure 
to 21 mmHg in repeated measurements.2 
The relationship between IOP and glaucomatous damage is critical to define the 
treatment of POAG. A vast array of studies support the idea that by reducing IOP is 
possible to inhibit the rate of progression of glaucomatous neuropathy. 
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Drug therapy is the first standard option to treat POAG.2 It reduces the risk of 
progressive loss of visual field in patients with early or advanced POAG and the 
development of defects in patients with ocular hypertension (OHT)3,4. The most 
recommended treatment in these cases is a beta-blocker eye drops or prostaglandin 
analogues such as latanoprost.2 Glaucoma patients often need to use topical therapy 
for many years. Hence, the adverse effects of drugs should be minimized to promote 
compliance with the prescribed treatment and therefore to allow the continuation of the 
therapy. Several epidemiological studies have shown that eye problems are common 
in patients treated with topical anti-glaucoma.4-7 Symptoms of discomfort seem to be 
associated with a long term use of drug against glaucoma, as it is described, that 
medication causes changes in the ocular surface and on the morphology of the 
corneal innervation.8-10 These adverse effects could be due to the active substance, 
and preservatives, but the mechanisms involved and the role of each components of 
topical preparations in inducing toxic or proinflammatory effects is still debated. 
The goal of our study is to describe the possible changes in corneal sensitivity, 
morphology subbasal plexus of the cornea and lacrimal functional unit with the use of 
unpreserved latanoprost (presentation in single-dose) in patients suffering from POAG 
or ocular hypertension. The effect of this drugs without the influence of the 
preservative has not been studied before. This analysis focused in a comprehensive 
way is essential to establish an objective and individualized therapeutic strategy to 
reduce the risks of the treatment and to improve the compliance with the results. 
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METHODS
Patients 
A prospective, clinical study was conducted. Before surgery, informed consent was 
obtained from each patient, and the study was carried out in accordance with the 
tenets of the Declaration of Helsinki and with the approval of the Ethics Committee of 
Consorci Sanitari de Terrassa Hospital de Terrassa (Barcelona, Spain).  
One eye of each patient was included and the sample was divided into 2 groups 
according to topical hypotensive therapy. In this way, control group (normal eyes), 
included 32 eyes of 32 healthy volunteers (13 male, 19 female; mean age,; 60 ± 11; 
range, 35 to 81 years), who met the following eligibility criteria: absence of current or 
previous local or systemic disease that could affect the cornea; no history of 
inflammatory eye disease, including infections; no previous eye surgery; no ocular 
trauma; no allergic pathology; no topical eye drops, and no contact lens use.  
Treatment group included 35 eyes of 35 patients (17 male, 18 female; mean age, 63 ± 
14; range, 35 to 89 years), treated with preservative-free topical latanoprost 
(Monoprost®;Laboratoires Thea, France). The inclusion criteria in this group were as 
follows: age 18 years or older, diagnosis of POAG or ocular hypertension treated for at 
least 3 months without changes in the medication used. The following exclusion 
criteria were used: severe ocular trauma at any time, previous history of intraocular 
surgery or argon laser trabeculoplasty, current use of contact lenses, history of recent 
ocular inflammation or infection, previous or current use of other ocular medication 
including artificial tear therapy, systemic treatment known to affect tear secretion, 
autoimmune disease, any history or slit-lamp evidence of eye surface disorders.  
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Clinical investigation 
All testing procedures took place at the same time of day, and under temperature and 
humidity controlled conditions. Detailed biomicroscopic examination of the anterior and 
posterior segments and ocular adnexa was performed. All measurements were 
performed under slit-lamp by the same investigator (A.D.C.F). Before doing the tests, 
all patients make a questionnaire. Questionnaire aimed at assessing, as separate 
concepts, the participants’ self-reported ocular symptoms. Thus, on the one hand, 
ocular symptoms were explored with a slightly modified version of the Salisbury Eye 
Evaluation Questionnaire.11 This six-item questionnaire included questions regarding 
symptoms of dryness, gritty or sandy sensation, burning sensation, redness, crusting 
eyelashes and eyes stuck shut in the morning. In addition to these symptoms, we 
included itchiness, as this symptom is commonly reported by dry eye patients and 
used in other DEQs.12 Patients were asked to grade each symptom from 0 to 4 in 
terms of frequency of occurrence, based on response options: never (0), rarely (1), 
sometimes (2), often (3) or all the time (4). We chose this questionnaire because it is 
simple and easy to be self-reported regardless of age or cultural level of the patient, 
although it does not included a comprehensive list of symptoms.13 Corneal sensitivity 
was studied using the Cochet-Bonnet esthesiometer. The monofilament had a 
diameter of 0.08 mm. The central zone was studied with perpendicular contact and 
with a length of 60 mm, decreasing in steps of 5 mm if a positive response was not 
obtained. Two positive responses in three attempts at each filament length were 
regarded as a positive result. Tear production was determined by the Schirmer I test 
and Break-up time was used as a measure of tear film stability. Fluorescein sating was 
carried out to detect injuries in the corneo-conjuntival epithelium. Oxford schema was 
used to grading them. The Tear break-up time of precorneal tear film after blinking was 
recorded. Tear break-up time was determined with preservative-free fluorescein drops 
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in order to avoid irritation.14 Fluorescence observation contrast was enhanced with a n. 
12 yellow Wratten filter and the mean of three consecutive video recorded 
measurements was used for our analysis. Tear osmolarity was measured using the 
TearLab Osmolarity System (TearLab Corp, San Diego, CA, USA). The lab-on-a-chip 
system of the instrument consists of a one-time-use test card, which collects 50 nL of 
tear sample and analyses it immediately to provide an osmolarity reading.15  All the 
eyes were examined with a digital corneal confocal laser-scanning microscope (HRT 
III Ros- tock Cornea Module; Heidelberg Engineering GmbH, Heidelberg, Germany), a 
laser scanning in vivo confocal microscopy (IVCM) that uses a 670-nm red wavelength 
helium neon diode laser source. The confocal laser scanning device uses a X 60 
objective water immersion lens and a working distance of 0 to 3 mm from the 
applanating cap. The images measure 400µm x 400 µm, and the manufacturer 
specifies an optical section thickness of 4µm. The module uses an entirely digital 
capture system. In vivo confocal microscopy was performed in the center of the cornea 
and it was carried out under topical anesthesia with oxybuprocaine 0.4% chlorhydrate 
(Novesina; Novartis Farma S.p.A., Varese, Italy) instilled in the lower conjunctival 
fornix before examination. Proper alignment and positioning of the head was 
maintained with the help of a dedicated target mobile red fixation light for the 
contralateral eye. A digital camera mounted on a side arm provided a lateral view of 
the eye and objective lens to monitor the position of the objective lens on the surface 
of the eye. A drop of 0.2% polyacrylic gel (Viscotirs Gel; Medivis, Catania, Italy) served 
as coupling medium between the polymethylmethacrylate contact cap of the objective 
and the cornea. At least 20 images in the central area of the corneal epithelium, sub-
basal plexus, and stroma were obtained for each eye. The procedure lasted 2 to 5 
minutes. A drop of antibiotic was instilled in the lower conjunctival fornix at the end of 
each examination. The cornea was then examined by slit-lamp to ensure its integrity.  
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The confocal images were evaluated in a masked manner, meaning that the 
investigator did not know to which group the images belonged. The best-focused and 
most representative images were selected and stored in digital format. The best 
images of each patient were saved irrespective of the state of the corneal layer and 
the mean of 3 to 5 images for each parameter was considered for statistical analysis.  
The following parameters were evaluated in IVCM images:  
1. Epithelial  Cell Density: cell density was evaluated in basal epithelium. Basal 
epithelium was considered 10 µm above Bowman layer. The cell count was 
performed within a region of interest of standardized dimensions (400µm x 400 µm) 
using the manual cell counting procedure offered in the software. Cells only 
partially contained in the area analyzed were not counted. The results were 
expressed in cells per square millimeter (cell/mm2) 
2. Number of Sub-basal Nerves: this parameter is defined as the sum of the nerve 
branches present in one image. The image of the sub-basal plexus having the 
highest number of recognizable nerve fibers was selected for each scan.  
3. Density  of Sub-basal Nerves:  defined as the total length of the nerves visible 
within a frame (expressed in mm/ mm2). 
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STATISTICAL ANALYSIS  
After an exploratory analysis, comparisons between groups were carried out applying 
Fisher’s exact test, Mann-Whitney test or Student t test, when appropriate. SPSS V19 
was used for statistical analysis and a significant level of p < 0.05 was considered. 
Normal variable distribution was assessed with the Kolmogorov–Smirnov test.
RESULTS  
Thirty control eyes of 30 patients completed the study. Mean age of these patients was 
60 ± 11; range 35-81years). In the treatment group 31 eyes of 31 patients (mean age 
63 ± 13; range 35-89) were finally included, from those, 25 (81%) with POAG and 6 
with ocular hypertension.  Mean time of treatment was 8 ± 6 months (range= 3-24 
months).  No significant differences in age and sex were found between groups. Six 
eyes of 6 patients, initially enrolled (2 eyes in the control group and 4 eyes in the 
treatment group), were excluded because of incomplete data. The demographic 
features of control group and treatment group are reported in Table 1. 
Table 1. Demographic Features of Control Group and Treatment Group
Control         
(n = 30)
Treatment Group    
(n = 31) P Value 
Age, y, mean ± SD
60 ± 11 
(35 to 81)
63 ± 13     
(35 to 89)
>0.05
Sex, ♀, ♂ 18 - 12 15 - 16 >0.05
Race caucasian caucasian -
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Clinical data (Schirmer I test, esthesiometry, tear break-up time, Tear osmolarity, 
symptoms and fluorescein staining test) for the treatment group and control 
groups are reported in Table 2, figure 1, 2 and 3. Statistically significant 
difference was found between treatment and control group in corneal sensitivity 
(p=0.000, Mann-Whitney test) and Tear break-up (p=0.000, Student t test). No 
statistically significant difference was found between treatment group and the 
control group in Schirmer I test and Tear osmolarity (p>0.05; Student t test). A 
statistically significant difference in the number of symptoms was observed 
between the control group and the treatment group (p=0.02; Mann-Whitney test). 
No statistically significant difference was found between treatment group and the 
control group in fluorescein staining test (p>0.05; Fisher’s exact test). 
Table 2. Clinical Data Comparison Between Control Group and Preservative-
free topical latanoprost Group
Control Treatment Group P Value 
Schirmer test, mm, mean ± SD 17 ± 6   15 ± 7 >0.05
BUT, s, mean ± SD 9 ± 5    5 ± 2 <0.05
Tear osmolarity, mOsmol/L, ± SD 310 ± 22 309 ± 20 >0.05
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Figure 1. Distribution of the corneal staining 
reported by the present sample (n = 61)
Figure 2. Distribution of corneal sensitivity 
reported by the present sample (n = 61)
Figure 3. Distribution of the number of 
symptoms reported by the present sample 
(n = 61)
 Control  
 Treatment Group 
 Control  
 Treatment Group 
 Control  
 Treatment Group 
In Vivo Confocal Microscopy for the treatment group and control groups are reported 
in (Table 3). Cell density of the basal epithelium in treatment group revealed a 
significant increase, with respect to control subjects (P =.008, Student t-test). The 
basal epithelium density (Figure 4) of treatment group was significantly higher than 
control group.  A significant reduction in the number of sub-basal nerves (Figure 5) 
was observed between the control group and the treatment group (P=.002, Student t-
test). The density of sub-basal nerves (Figure 4) was significantly lower in group of 
treatment group, with respect to control subjects (P =.005, Student t-test). 
 
Table 3. In Vivo Confocal Microscopy Data Between Control Group and 
Preservative-free topical latanoprost Group
Control Treatment Group P Value 
Basal epithelium, cell/mm2, (mean ± 
SD)  (minimun to maximum)
4983 ± 588             
3880 to 6066 
5564 ± 1013           
3625 to 7629 <0.05
Number /mm2, mean ± SD           
(minimun to maximum)
34 ±  10                      
12 to 56
26 ± 9                         
12 to 44
<0.05
Density mm/mm2, mean ± SD     
(minimun to maximum)
16 ± 5                           
4 to 29
13 ± 4                           
4 to 23
<0.05
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Figure 4. IVCM images (400µm x 400µm) of corneal sub-basal nerves. Examples of 
sub-basal nerves density and number evaluation. The tracing of subbasal nerves was 
performed using NeuronJ (pink), a semiautomatic ImageJ plug in to facilitate the 
tracing and quantification of elongated image structures. Then, the total sub-basal 
nerves density was measured automatically. Left: control group, Right: treatment 
group. 
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Figure 5. The basal epithelial layer images showed significant increase of cell density 
in preservative-free topical latanoprost patients with respect to control group. (Top left) 
control group density = 3928 ±60 cell/mm2, (Top right) control group density = 4862 
±60 cell/mm2, (Bottom left) preservative-free topical latanoprost patients group density 
= 6250 ± 60 cell/mm2, and (Bottom right) preservative-free topical latanoprost patients 
group density = 6522 ± 60 cell/mm2. 
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DISCUSSION 
The aim of the present study was to compare clinical test results and in vivo confocal 
microscopy features in POAG or ocular hypertension patients on glaucoma therapy 
with preservative-free topical latanoprost for at least 3 months and in untreated 
controls. Since current medical treatment for glaucoma requires topical medication for 
a long period of time, chronic side effects are a major concern. Among these side 
effects, ocular surface disorders are relatively common, caused either by the drug 
itself or by preservatives.16,17 Latanoprost are currently the most commonly prescribed 
compounds for glaucoma therapy.17-20 Side effects of latanoprost include cystoid 
macular edema, choroidal detachment, anterior uveitis, hyperpigmentation of 
eyelashes and iris, superficial punctate keratitis, and herpes simplex dendritic keratitis. 
21-27 These effects could be attributable to the active component as well as to 
preservatives.28 The toxic action of preservatives on the eye surface has been widely 
demonstrated5 and these side effects may be related to preservative concentration, 
duration of use, and number of instillations.7 Ubels and associates demonstrated that 
preservative-free artificial tear solutions promote recovery of damaged corneal 
epithelium barrier faster than other commercial artificial tears.29 Manni and associates 
showed a significant increase in Interleukin-1β in a group of patients treated with 
preserved timolol compared to one treated with preservative-free timolol.30 Noecker 
and associates showed that antiglaucoma drugs containing low preservative 
concentrations were associated with less inflammatory infiltrate in the rabbit 
conjunctiva.31 Berdy used scanning electron microscopy to compare the effect of 2 
preservative-free artificial tear preparations and 0.02% solution of benzalkonium 
chloride on the corneal epithelium of rabbit eyes: corneas subjected to mild treatment 
with the benzalkonium chloride solution showed loss of microvilli, increased number of 
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epithelial holes, and loss of hexagonal shape. Corneas treated with an exaggerated 
dose of benzalkonium chloride exhibited diffuse cell peeling, retraction of cell 
membrane borders, destruction of microvilli, and loss of the superficial layer of the 
corneal epithelium.32 Many clinical studies on humans confirm these laboratory results. 
Pisella and associates showed that use of preserved eye drops greatly increases the 
frequency of ocular irritation in glaucoma patients. The frequency of signs and 
symptoms was correlated with the number of preserved eye drops used.5 Baudouin 
confirmed that the frequency of eye symptoms and signs of ocular surface irritation 
were higher in patients treated with preserved than preservative-free eye drops and 
the change from preserved to preservative-free preparation was associated with a 
significant decrease in ocular irritation.33 On the contrary, Kuppens and associates 
demonstrated that tear break-up time was significantly lower in patients treated with 
preserved and preservative-free timolol than in controls and did not differ significantly 
from each other, suggesting that the active compound may alter the tear film, while 
benzalkonium chloride may have other side effects.34 In our study, the clinical results, 
excluding the Schirmer I test and Tear osmolarity, showed statistically significant 
differences between treatment group and control group. Traditional methodological 
clinical and instrumental diagnostics are unsatisfactory for in vivo study of the ocular 
surface at cell level, and the use of in vivo confocal microscopy permits a new 
approach to the study of corneal morphology. In vivo confocal microscopy is not 
particularly invasive and is quickly performed, safe, and repeatable. In the present 
study, we performed extensive examination of ocular surface by in vivo confocal 
microscopy to investigate the toxic effects of chronic glaucoma therapy.  Although the 
morphologic appearances of corneal nerves in ocular surface diseases have been 
described using these parameters, very few studies have evaluated the relationship 
between this morphological evaluation and corneal sensation in dry eyes.35–37 In 
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addition, only one study has evaluated this relationship in patients treated for 
glaucoma or ocular hight tension.38 Our study also offers a systematic evaluation of 
images, based on parameters that can be analyzed quantitatively. Our evaluation of 
corneal damage showed that preservative-free latanoprost produced significantly 
surface damage. The effects of the former were significantly different from that of the 
control group. Martone and associates demonstrated that the increase density of basal 
epithelial cells in no-preservative beta-blockers group was not significantly than in the 
control group.9 Nevertheless, Roman, Meda and associates in involving animal and 
human scleral tissues exposed to prostaglandins demonstrated significant matrix 
metalloproteinases up-regulation and tissue inhibitors of matrix metalloproteinases 
down regulation with the corresponding altered gene expression, suggesting that 
prostaglandins stimulate extracellular matrix degradation of ocular surface tissue by 
modulating the balance between these enzyme. 39,40 Also, in our study the increase 
density of basal epithelial cells, showed statistically significant differences between 
treatment group and control group. This epithelial cell modification could determine the 
stromal changes. In fact, the inflammatory process involving the eye surface could 
induce stromal apoptotic phenomena and increased stromal proteolytic activity. This in 
turn could stimulate proliferation leading to keratocyte activation and secretion of 
neural growth factors contributing to changes in nerve number and shape. Indeed, 
patients on glaucoma therapy had fewer sub-basal corneal nerves than controls. 
Nerve fibers are important for corneal trophism and help maintain a healthy corneal 
surface41,42 and the lower number and density of nerves in the sub-basal level may 
explain the lower corneal sensitivity observed in treatment group. It is interesting that 
the reduced number of nerves of sub-basal fibers was correlated with corneal 
hypoesthesia and reduced tear secretion. The number of nerves observed in treatment 
group found in our study is similar to those of Grupcheva and associates43 and 
!18
Oliveira-Soto and Efron.38 As several studies have demonstrated equivalent efficacy of 
IOP-lowering medications in the presence and absence of preservatives, the selection 
of ocular hypotensive drugs containing formulation components with low levels of 
cytotoxicity may reduce damage to the conjunctiva and cornea, especially over the 
course of chronic treatment. Exclusive use of preservative-free eye drops or even a 
reduction in the number of preserved eye drops used reduce the signs of ocular 
surface irritation in glaucoma patients.6 There are some issues to consider before 
drawing any final conclusions. One of the limitations of this study is that it is not a 
clinical trial and that a double-masked analysis was not performed. However, it is 
important to consider that patients have been diagnosed before starting the study and 
in this case a double-masked analysis is not possible.  In any case, further research 
will be important to establish more accurately the magnitude of the differences. 
Another limitation was that the measurements of in vivo confocal microscopy were 
made in the center of the cornea. The results may be different in the corneal periphery 
but with this technique better images are obtained in the center, and the exact 
recognition of the depth of the optical section in the stroma was not possible.  
The development of alternative, nontoxic preservatives and preservative-free 
preparations has improved and will continue to improve the overall safety profile of 
IOP-lowering medications. Cytotoxicity in the ocular surface cells is a well-known 
detrimental effect induced by benzalkonium chloride containing antiglaucoma agents. 
There are numerous studies describing the advantages of free-preservative 
formulation in eye drops, but usually studies do not focus on other excipients besides 
benzalkonium chloride.44-46 Conjunctival hyperaemia due to vessel dilatation is one of 
the most common side effects caused by prostaglandins and prostamids 47,48, but 
otherwise, these compounds are well tolerated in long-term use. Prostaglandins have 
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even been claimed to act as non-specific cytoprotectors against benzalkonium chloride 
toxicity.49 The use of preservative-free antiglaucoma drops is even more important if 
glaucoma surgery is planned. Filtration surgery for glaucoma may be unsuccessful in 
patients with a long history of antiglaucoma treatment, especially multidrug treatment.
50 It is suspected that the toxicity of the preservatives contained in antiglaucoma drops 
has a role in the failure of surgical treatment.51 To our knowledge, no previous studies 
have analize the effects of free-preservative prostaglandins on ocular surface. In our 
study we provide evidence of ocular surface changes with free-preservative 
prostaglandins. Currently, popularity of free-preservative formulations in ocular drops 
has increased in the clinics due to their lower side effects and better patient 
compliance. Therefore, it is important that all, excipients and drugs, in ocular drop 
formulations should be evaluated, since some of these agents exert detrimental effects 
on ocular surface.  More research is needed into understand aspects such as the 
toxicity of the active drug and mechanisms of this toxicity. 
Declaration of interest: The authors report no conflicts of interest. The authors alone 
are responsible for the content and writing of the paper.  
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